FDA Grants Accelerated Approval to Gilead's Hepcludex® , the First and Only Approved Treatment for Chronic Hepatitis Delta Virus
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-1 Inhibitors
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
NevGold Congratulates Perpetua Resources On US$2.9 Billion Loan for the Gold-Antimony Stibnite Project in Idaho; NevGold Rapidly Advancing its At-Surface Oxide, Antimony-Gold Limo Butte Project to Near-Term U.S. Production
